TATA-box-binding protein-associated factor 15 is a novel biomarker that promotes cell proliferation and migration in gastrointestinal stromal tumor

BACKGROUND Gastrointestinal stromal tumor (GIST) is a common neoplasm with high rates of recurrence and metastasis, and its therapeutic efficacy is still not ideal. There is an unmet need to find new molecular therapeutic targets for GIST. TATA-box-binding protein-associated factor 15 (TAF15) contributes to the progress of various tumors, while the role and molecular mechanism of TAF15 in GIST progression are still unknown. AIM To explore new molecular therapeutic targets for GIST and understand the biological role and underlying mechanisms of TAF15 in GIST progression. METHODS Proteomic analysis was performed to explore the differentially expressed proteins in GIST. Western blotting and immunohistochemical analysis were used to verify the expression level of TAF15 in GIST tissues and cell lines. Cell counting kit-8, colony formation, wound-healing and transwell assay were executed to detect the ability of TAF15 on cell proliferation, migration and invasion. A xenograft mouse model was applied to explore the role of TAF15 in the progression of GIST. Western blotting was used to detect the phosphorylation level and total level of RAF1, MEK and ERK1/2. RESULTS A total of 1669 proteins were identified as differentially expressed proteins with 762 upregulated and 907 downregulated in GIST. TAF15 was selected for the further study because of its important role in cell proliferation and migration. TAF15 was significantly over expressed in GIST tissues and cell lines. Overexpression of TAF15 was associated with larger tumor size and higher risk stage of GIST. TAF15 knockdown significantly inhibited the cell proliferation and migration of GIST in vitro and suppressed tumor growth in vivo. Moreover, the inhibition of TAF15 expression significantly decreased the phosphorylation level of RAF1, MEK and ERK1/2 in GIST cells and xenograft tissues, while the total RAF1, MEK and ERK1/2 had no significant change. CONCLUSION TAF15 is over expressed in GIST tissues and cell lines. Overexpression of TAF15 was associated with a poor prognosis of GIST patients. TAF15 promotes cell proliferation and migration in GIST via the activation of the RAF1/MEK/ERK signaling pathway. Thus, TAF15 is expected to be a novel latent molecular biomarker or therapeutic target of GIST.

[1]  Li Tao,et al.  Prognostic significance of serum CA125 in the overall management for patients with gastrointestinal stromal tumors , 2023, BMC Gastroenterology.

[2]  Z. Zhao,et al.  Efficacy of SCF drug conjugate targeting c-KIT in gastrointestinal stromal tumor , 2022, BMC Medicine.

[3]  J. Lunec,et al.  p53 as a biomarker and potential target in gastrointestinal stromal tumors , 2022, Frontiers in Oncology.

[4]  Yingyong Hou,et al.  Role of Surgery in the Management of Liver Metastases From Gastrointestinal Stromal Tumors , 2022, Frontiers in Oncology.

[5]  Yoon-Koo Kang,et al.  Clinical outcomes and prognostic factors for patients with high‐risk gastrointestinal stromal tumors treated with 3‐year adjuvant imatinib , 2022, International journal of cancer.

[6]  Chuanbin Yang,et al.  LncRNA MIR9-3HG enhances LIMK1 mRNA and protein levels to contribute to the carcinogenesis of lung squamous cell carcinoma via sponging miR-138-5p and recruiting TAF15. , 2022, Pathology, research and practice.

[7]  Qingyuan Liu,et al.  LncRNA LINC00649 recruits TAF15 and enhances MAPK6 expression to promote the development of lung squamous cell carcinoma via activating MAPK signaling pathway , 2022, Cancer Gene Therapy.

[8]  Tobias Österlund,et al.  FET fusion oncoproteins interact with BRD4 and SWI/SNF chromatin remodelling complex subtypes in sarcoma , 2022, Molecular oncology.

[9]  Fugeng Zhang,et al.  LncRNA APOA1-AS facilitates proliferation and migration and represses apoptosis of VSMCs through TAF15-mediated SMAD3 mRNA stabilization , 2021, Cell cycle.

[10]  T. Triche,et al.  Dysregulated heparan sulfate proteoglycan metabolism promotes Ewing sarcoma tumor growth , 2021, bioRxiv.

[11]  L. Wan,et al.  RAF-MEK-ERK pathway in cancer evolution and treatment. , 2021, Seminars in cancer biology.

[12]  W. Peng,et al.  LncRNA GAS5 activates the HIF1A/VEGF pathway by binding to TAF15 to promote wound healing in diabetic foot ulcers , 2021, Laboratory Investigation.

[13]  Pilong Li,et al.  Loci-specific phase separation of FET fusion oncoproteins promotes gene transcription , 2021, Nature Communications.

[14]  C. Zhuang,et al.  BDNF expression in GISTs predicts poor prognosis when associated with PD-L1 positive tumor-infiltrating lymphocytes , 2021, Oncoimmunology.

[15]  Zongxian Zhao,et al.  Novel Prognostic Nomogram for Recurrence-Free Survival of Patients With Primary Gastrointestinal Stromal Tumors After Surgical Resection: Combination of Prognostic Nutritional Index and Basic Variables , 2021, Frontiers in Oncology.

[16]  E. Keung,et al.  The Landmark Series: Systemic Therapy for Resectable Gastrointestinal Stromal Tumors , 2020, Annals of Surgical Oncology.

[17]  D. Hallahan,et al.  TAF15 contributes to the radiation-inducible stress response in cancer , 2020, Oncotarget.

[18]  C. Tzen,et al.  Clinical Diagnosis of Gastrointestinal Stromal Tumor (GIST): From the Molecular Genetic Point of View , 2019, Cancers.

[19]  R. Yaeger,et al.  Targeting Alterations in the RAF-MEK Pathway. , 2019, Cancer discovery.

[20]  J. Fletcher,et al.  Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours , 2019, British Journal of Cancer.

[21]  Robin L. Jones,et al.  Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  M. Heinrich,et al.  Translational insights into gastrointestinal stromal tumor and current clinical advances , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  Robin L. Jones,et al.  Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  L. Shen,et al.  Chinese consensus guidelines for diagnosis and management of gastrointestinal stromal tumor , 2017, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[25]  S. Nishizuka,et al.  α-Amanitin Restrains Cancer Relapse from Drug-Tolerant Cell Subpopulations via TAF15 , 2016, Scientific Reports.

[26]  J. Jónasson,et al.  KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  L. Tora,et al.  TAF15 is important for cellular proliferation and regulates the expression of a subset of cell cycle genes through miRNAs , 2013, Oncogene.

[28]  J. Lasota,et al.  Gastrointestinal stromal tumors. , 2013, Gastroenterology clinics of North America.

[29]  J. Blay,et al.  Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.

[30]  A. Guialis,et al.  Domains involved in TAF15 subcellular localisation: dependence on cell type and ongoing transcription. , 2012, Gene.

[31]  Aki Vehtari,et al.  Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. , 2012, The Lancet. Oncology.

[32]  H. Vollmers,et al.  Diagnostic and therapeutic potential of a human antibody cloned from a cancer patient that binds to a tumor-specific variant of transcription factor TAF15. , 2010, Cancer research.

[33]  A. Ståhlberg,et al.  The multifunctional FUS, EWS and TAF15 proto-oncoproteins show cell type-specific expression patterns and involvement in cell spreading and stress response , 2008, BMC Cell Biology.

[34]  T. Glisovic,et al.  RNA‐binding proteins and post‐transcriptional gene regulation , 2008, FEBS letters.

[35]  H. Gehring,et al.  Identification and characterization of the nuclear localization/retention signal in the EWS proto-oncoprotein. , 2006, Journal of molecular biology.

[36]  G. Hicks,et al.  TLS, EWS and TAF15: a model for transcriptional integration of gene expression. , 2006, Briefings in functional genomics & proteomics.

[37]  S. L. Wong,et al.  Towards a proteome-scale map of the human protein–protein interaction network , 2005, Nature.

[38]  S. Nunobe,et al.  Surgery including liver resection for metastatic gastrointestinal stromal tumors or gastrointestinal leiomyosarcomas. , 2005, Japanese journal of clinical oncology.

[39]  M. Mann,et al.  RNA and RNA Binding Proteins Participate in Early Stages of Cell Spreading through Spreading Initiation Centers , 2004, Cell.

[40]  Samuel Singer,et al.  PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors , 2003, Science.

[41]  L. Sobin,et al.  Diagnosis of gastrointestinal stromal tumors: A consensus approach. , 2002, Human pathology.

[42]  J. Lasota,et al.  Gastrointestinal stromal tumors: recent advances in understanding of their biology. , 1999, Human pathology.

[43]  D. Immanuel,et al.  TLS (FUS) binds RNA in vivo and engages in nucleo-cytoplasmic shuttling. , 1997, Journal of cell science.